Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Key Takeaway 2: Initial Systemic Therapy in HCC

Key Takeaway 1: Multidisciplinary Management of HCC

The FDA has approved pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (combined positive score ≥10) as determined by an FDA-approved test, with disease progression after ≥1 prior lines of systemic therapy.

FDA Approves Pembrolizumab for PD-L1+ Esophageal Cancer

In the phase III PROSPER trial, investigators will attempt a novel approach in localized renal cell carcinoma: priming the immune system prior to nephrectomy with neoadjuvant nivolumab and continuing with adjuvant blockade. The study will be the first to combine neoadjuvant and adjuvant immunotherapy with standard of care nephrectomy.

Investigators Seek to Boost Surgical Cures in RCC With Immune Priming

Drug Development and Final Thoughts

Novel and Combination Therapies for the Treatment of Gastric Cancer

Interpretation of Data on Immunotherapy Use in Gastric Cancer

The Role of Immunotherapy in Gastric Cancer

Ramucirumab for Progressive Disease in Gastric Cancer

Place for Surgery and Poor Prognosis

Differentiating Among the Types of Surgery

Surgery Options in Locally Advanced Gastric Cancer

Trastuzumab in HER2-Positive Gastroesophageal Cancer

First-Line Therapy in HER2-Negative Gastric Cancer

Treatment in HER2-Positive Disease and Dosing Preferences

Factors Determining Initial Treatment Approach for Gastric Cancer

Molecular Testing Used for Gastric Cancer

Genetic Risk, Screening, and Diagnosis for Gastric Cancer

Introduction and Global Trends of Gastric Cancer

Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.

Immunotherapy Research Continues to Emerge in Urothelial Cancer

Immuno-Oncology

Immuno-Oncology | Specialty